RecruitingNCT03263130

Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap


Sponsor

Gelb, Arthur F., M.D.

Enrollment

60 participants

Start Date

Jan 1, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).


Eligibility

Min Age: 30 Years

Inclusion Criteria4

  • asthma- copd overlap
  • emphysema in smokers with smoking history \> 15 pack years
  • COPD/ bronchitis and bronchiectasis in smokers with smoking history
  • \>15 pack years

Exclusion Criteria3

  • non smokers
  • any other pulmonary diagnosis
  • pulmonary fibrosis

Interventions

OTHERAs above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap

Locations(2)

Arthur F Gelb MD

Lakewood, California, United States

Arthur F Gelb MD

Lakewood, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03263130


Related Trials